New York, May 26, 2026, 19:03 (EDT)
Zenas BioPharma shares ended lower on Tuesday, lagging a firmer biotech tape as investors looked past the long U.S. market weekend and toward a June presentation for its lead autoimmune drug.
The Nasdaq-listed stock was quoted at $18.73, down about 1.3%, after trading between $18.61 and $19.27. Its 52-week range runs from $8.91 to $44.60, underscoring how much trial news still drives the name.
The timing matters. U.S. stock markets were closed on Monday for Memorial Day, and Tuesday’s session reopened the tape less than two weeks before Zenas is due to present detailed Phase 3 data for obexelimab at the EULAR rheumatology congress in London on June 4.
That presentation is the next visible marker for a company whose valuation is still tied largely to clinical progress rather than product sales. Zenas has said obexelimab’s safety and efficacy results in immunoglobulin G4-related disease, or IgG4-RD, will be presented by Emanuel Della Torre of Vita-Salute San Raffaele University. IgG4-RD is a rare immune disease that can inflame and scar multiple organs.
The broader biotech market gave Zenas little help as a stock-specific trade. The SPDR S&P Biotech ETF, an exchange-traded fund that tracks a basket of biotech stocks, was up 1.3%, while Amgen shares fell about 1.0%.
Zenas has said the INDIGO Phase 3 trial, a late-stage human study often used to support drug approval filings, showed obexelimab cut the risk of IgG4-RD flare by 56% versus placebo over 52 weeks. The company also said the drug met four secondary goals and showed no new safety signals.
In its May 13 update, Zenas said it remained on track to submit a Biologics License Application, the FDA filing used to seek approval for biologic medicines, this quarter and a European marketing application in the second half of 2026. Founder and CEO Lonnie Moulder said the company expected “important clinical and regulatory milestones” over the next three quarters. Zenas BioPharma, Inc
The competitive bar is plain. Amgen’s Uplizna is already FDA-approved for adults with IgG4-RD and Amgen said that drug reduced flare risk by 87% in its own trial. That cross-trial comparison has weighed on Zenas since January, even though such comparisons can be imperfect because studies may enroll different patients.
Jefferies analyst Roger Song had written ahead of the readout that obexelimab likely needed a 65% flare-risk reduction to prove “commercially viable,” BioPharma Dive reported. Zenas reported 56%. The shortfall helps explain why the stock remains well below its 52-week high despite the trial formally succeeding. BioPharma Dive
But the downside case is still there. Regulators could ask for more evidence, the EULAR details may not change investor views, and Amgen’s approved drug may set a higher commercial hurdle than Zenas can clear. Zenas is also still spending heavily: it reported a first-quarter net loss of $81.0 million, though it said cash, equivalents and investments of $718.5 million, plus expected financing items, could fund operations at least through the second quarter of 2029.
For now, the stock is trading like a catalyst story, not a broad biotech rally story. The next test is whether the London data give investors a cleaner case for obexelimab before the FDA filing window closes.
